Plus Orphan Status for Treatment of Leptomeningeal Metastases in Lung Cancer

  Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company” or “Plus Therapeutics”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announces that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Rhenium (186Re) Obisbemeda for the treatment of leptomeningeal metastases (LM) in patients with lung cancer.

https://www.globenewswire.com/news-release/2025/03/06/3038083/0/en/Plus-Therapeutics-Granted-U-S-FDA-Orphan-Drug-Designation-for-Rhenium-186Re-Obisbemeda-for-the-Treatment-of-Leptomeningeal-Metastases-in-Patients-with-Lung-Cancer.html